OptiNose

OptiNose PP&E per Employee

Delisted

The PP&E per Employee of OptiNose (OPTN) as of Nov 11, 2026 is 6,259.84 USD. In the previous year, PP&E per Employee was 10,606.30 USD — a change of -40.98% (lower).

PP&E per Employee

6,259.84USD

YoY

-40.98%

Last updated:

PP&E per Employee of OptiNose is 2022 6,259.84 USD. PP&E per Employee of OptiNose was 2021 10,606.30 USD. It decreases by -40.98% lower compared to the previous year.

The OptiNose PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2015
1,503.94 USD
Jan 1, 2016
2,543.31 USD
Jan 1, 2017
20,188.98 USD
Jan 1, 2018
30,582.68 USD
Jan 1, 2019
34,944.88 USD
Jan 1, 2020
15,968.50 USD
Jan 1, 2021
10,606.30 USD
Jan 1, 2022
6,259.84 USD
The OptiNose PP&E per Employee history
YEARPP&E per EmployeeYoY
6,259.84USD-40.98%
10,606.30USD-33.58%
15,968.50USD-54.30%
34,944.88USD+14.26%
30,582.68USD+51.48%
20,188.98USD+693.81%
2,543.31USD+69.11%
1,503.94USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiNose Stock analysis

What does OptiNose do? OptiNose, Inc. develops and commercializes pharmaceutical products for ear, nose, and throat specialists and allergy specialists. The company's lead product, XHANCE (fluticasone propionate) nasal spray, uses a breath powered exhalation delivery system to treat chronic rhinosinusitis with nasal polyps. XHANCE is marketed as a topically acting anti-inflammatory corticosteroid that delivers medication directly to the site of inflammation. The company also has product candidates including XHANCE for chronic sinusitis, OPN-300, and OPN-021, which are part of its pipeline for ENT and allergy treatments. XHANCE is the company's primary revenue-generating product, targeting ENT and allergy specialists who prescribe it to patients with chronic rhinosinusitis and nasal polyps. The product's differentiated clinical profile positions it as a potential standard of care in its therapeutic area. Other pipeline products like OPN-300 and OPN-021 are in development but not yet commercialized, so they do not contribute to current revenue streams. The company's business model relies on the commercialization of XHANCE, which is sold to healthcare providers and patients through pharmaceutical distribution channels. ENT and allergy specialists are the key buyers of XHANCE, as it is designed specifically for their patient populations. The company's focus on nasal polyps and chronic sinusitis treatments aligns with the needs of these medical specialists. OptiNose is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OptiNose stock

PP&E per Employee of OptiNose is 6,259.84 USD in 2022.

PP&E per Employee of OptiNose changed from 10,606.30 USD to 6,259.84 USD, representing a -40.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee OptiNose since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's OptiNose historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — OptiNose

All Key Metrics — OptiNose